Business Description
TriSalus Life Sciences Inc
NAICS : 339112
SIC : 3845
ISIN : US89680M1018
Total Employee Number:
102Description
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.64 | |||||
Equity-to-Asset | 0.18 | |||||
Debt-to-Equity | 2.69 | |||||
Debt-to-EBITDA | -1.65 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.2 | |||||
Beneish M-Score | -3.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69 | |||||
3-Year EBITDA Growth Rate | 82.1 | |||||
3-Year EPS without NRI Growth Rate | 78 | |||||
3-Year FCF Growth Rate | 83.3 | |||||
3-Year Book Growth Rate | 53.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 36.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.68 | |||||
9-Day RSI | 52.84 | |||||
14-Day RSI | 53.11 | |||||
3-1 Month Momentum % | -12.96 | |||||
6-1 Month Momentum % | -25.92 | |||||
12-1 Month Momentum % | -14.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.78 | |||||
Quick Ratio | 5.46 | |||||
Cash Ratio | 4.8 | |||||
Days Inventory | 197.21 | |||||
Days Sales Outstanding | 45.21 | |||||
Days Payable | 171.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.9 | |||||
Shareholder Yield % | -27.94 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 85.07 | |||||
Operating Margin % | -62.45 | |||||
Net Margin % | -60.85 | |||||
EBITDA Margin % | -46.67 | |||||
FCF Margin % | -45.22 | |||||
OCF Margin % | -44.54 | |||||
ROA % | -64.2 | |||||
ROIC % | -498.08 | |||||
3-Year ROIIC % | -41.41 | |||||
ROC (Joel Greenblatt) % | -618.14 | |||||
ROCE % | -68.39 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.02 | |||||
PB Ratio | 20.43 | |||||
Price-to-Tangible-Book | 20.33 | |||||
EV-to-EBIT | -11.15 | |||||
EV-to-Forward-EBIT | -20.94 | |||||
EV-to-EBITDA | -11.47 | |||||
EV-to-Forward-EBITDA | 56.87 | |||||
EV-to-Revenue | 5.35 | |||||
EV-to-Forward-Revenue | 4.73 | |||||
EV-to-FCF | -11.83 | |||||
Price-to-GF-Value | 0.99 | |||||
| Price-to-Net-Current-Asset-Value | 26.69 | |||||
Earnings Yield (Greenblatt) % | -8.97 | |||||
FCF Yield % | -7.74 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TLSI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TriSalus Life Sciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 44.883 | ||
| EPS (TTM) ($) | -1.41 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 81.21 | ||
| 14-Day RSI | 53.11 | ||
| 14-Day ATR ($) | 0.306934 | ||
| 20-Day SMA ($) | 4.2905 | ||
| 12-1 Month Momentum % | -14.26 | ||
| 52-Week Range ($) | 2.2 - 7.95 | ||
| Shares Outstanding (Mil) | 61.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TriSalus Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TriSalus Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 113 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 112 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | In 14 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 13 days | ||
| General meeting for 2026 | 2026-05-14 10:00 | 2.67 (-25.83%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 16:30 | 4.54 (+2.02%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 4.54 (+2.02%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 16:30 | 5.00 (+0.20%) | ||
| Annual report for 2025 | 2026-03-05 | 5.00 (+0.20%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 | 5.00 (+0.20%) |
Show
Entries
TriSalus Life Sciences Inc Frequently Asked Questions
What is TriSalus Life Sciences Inc(TLSI)'s stock price today?
The current price of TLSI is $4.27. The 52 week high of TLSI is $7.95 and 52 week low is $2.20.
When is next earnings date of TriSalus Life Sciences Inc(TLSI)?
The next earnings date of TriSalus Life Sciences Inc(TLSI) is 2026-08-06.
Does TriSalus Life Sciences Inc(TLSI) pay dividends? If so, how much?
TriSalus Life Sciences Inc(TLSI) does not pay dividend.
Guru Commentaries on NAS:TLSI
No articles.
Press Release
Articles on TriSalus Life Sciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers